Mustang Bio, Inc. ( MBIO ) shares appear to be trending upward Tuesday on continued momentum after the company on Monday announced safety and efficacy data from its Phase 1/2 clinical trial of MB-106, a possible treatment for certain types of blood cancer.

90% of patients treated with MB-106 responded to the treatment with three complete responses. Out of the three complete responses, one of the participants remains in complete remission at 31 months.

Mustang Bio ( MBIO ) is developing the treatment in collaboration with Fred Hutch Cancer Center. The data was presented at the European Hematology Association 2024 Hybrid Congress.

See Also: 12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

MBIO Price Action: Mustang Bio ( MBIO ) stock is trading 35.9% higher at 99 cents at the time of writing, according to data from Benzinga Pro.

Image: Emilian Danaila from Pixabay